Safety of insulin analogs during pregnancy: a meta-analysis
- 1.8k Downloads
The objective of this study was to assess the safety of four insulin analogs (aspart, lispro, glargine, and detemir) for the treatment of diabetes in pregnancy.
We searched Embase, Pubmed, and the Cochrane Central Register for Controlled Trials database through May 31, 2014. All articles were reviewed by two independent researchers, and if a discrepancy was noted, a third researcher was consulted. Results data were summarized by RevMan 5.2 software.
Our search resulted in the retrieval and screening of 3519 studies. Of those, 24 studies met the eligibility criteria; the studies reported on a total of 3734 women with pre-gestational or gestational diabetes during pregnancy. The use of lispro was associated with lower rates of neonatal jaundice (RR = 0.63) and severe maternal hypoglycemia (RR = 0.33) than regular insulin. Lispro use was also associated with higher birth weight (WMD = 116.44) and an increased incidence of large for gestational age (LGA) births (RR = 1.42) compared with regular insulin. Rates of cesarean section and macrosomia were similar in pregnant women treated with aspart and regular insulin. Birth weights and rates of severe maternal hypoglycemia, respiratory dysfunction syndrome, and neonatal intensive care unit admission were similar after pregnant women were treated with glargine and NPH insulin. Rates of LGA, macrosomia, and neonatal hypoglycemia were similar after pregnant women were treated with detemir and NPH insulin.
Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study. However, lispro was related to higher birth weight and increased rate of LGA in neonates. More high-quality randomized controlled trials are needed to clarify the best treatment options for diabetes during pregnancy.
KeywordsInsulin analogs Pregnancy Meta
Conflict of interest
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled, “Safety of insulin analogs during pregnancy: a meta-analysis.”
- 2.DeSisto CL, Kim SY, Charma AJ (2014) Prevalence estimates of gestational diabetesmellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Prev Chronic Dis 19(11):E104Google Scholar
- 8.Aydin Y, Berker D, Direktor N et al (2008) Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 80(44):4–448Google Scholar
- 14.Balaji V, Balaji MS, Alexander C et al (2010) Premixed insulin aspart 30 (Bia sp 30) vs premixed human insulin 30 (Bhi 30) in gestational diabetes mellitus—a pilot study. J Assoc Physician India 58:99–101Google Scholar
- 23.Imbergamo MP, Amato MC, Amodeo R et al (2012) Use of basal insulin analog detemir in pregnant women with type1 diabetes:a case-control retrospective study. Giorn Ital Ostet Ginecol 34:491–498Google Scholar